Byotrol Plc
("Byotrol" or the "Company")
Secondary Trading on Asset Match Following Cancellation
Byotrol Plc is pleased to announce that Asset Match (www.assetmatch.com) have been appointed to facilitate secondary trading in the New Ordinary shares following the upcoming cancellation of admission to trading on AIM (the "Cancellation").
As previously announced, following approval by shareholders at the General Meeting held on 22nd April 2024, the Cancellation will take effect from 7.00 a.m. on 30th April 2024.
Following the Cancellation, the New Ordinary shares will be admitted to trading on the off-market dealing facility on 30th April 2024.
Asset Match, a firm Authorised and Regulated by the Financial Conduct Authority (FRN 579310), will operate an electronic off-market dealing facility for the New Ordinary shares. This facility will allow existing shareholders of the Company ("Shareholders") and new investors to trade the New Ordinary shares by matching buyers and sellers through periodic auctions.
Investors are encouraged to register on www.assetmatch.com and add Byotrol Plc to their 'Watchlist' to continue to receive Company updates and auction/price information.
The Asset Match trading facility operates under its own code of practice which governs the behaviour of participants and the running of the periodic auctions. Asset Match operates an open auction system where volumes of bids and offers at different prices are displayed on-screen together with the closing date of the auction. At the end of each auction period, Asset Match passes this information through a non-discretionary algorithm that determines a "market-derived" single clearing price ("Share Price") based on supply and demand and allocates transactions accordingly. Bids and offers may be made, amended and withdrawn at any time before the closing date of each auction.
Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. Shareholders wishing to trade shares through Asset Match must do so through a stockbroker. A comprehensive list of stockbrokers who have signed up to access the Asset Match platform is available on request.
Full details will be made available to Shareholders on the Company's website at www.byotrol.com. Investors may contact Asset Match in relation to any queries regarding trading via the secondary market trading facility by emailing dealing@assetmatch.com.
Further details of the Cancellation and re-registration were set out in the circular dated 28 March 2024 ("the Circular"). A copy of the Circular is available on the Company's website www.byotrol.com
Unless otherwise indicated, defined terms in this announcement shall have the same meaning as described in the Circular.
For further information contact:
Byotrol Plc | |
Ashley Head, Non- Executive Chairman | +44 (0)1925 742 000 |
David Traynor, Interim Chief Executive Officer Chris Sedwell, Chief Financial Officer
| |
| |
Asset Match | +44 (0)20 7248 2788 |
Ben Weaver Hannah Woodley
| |
| |
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the animal and human healthare, industrial, institutional and consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, go to byotrol.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.